EGFRMutations in Small-Cell Lung Cancers in Patients Who Have Never Smoked
Authors:
- Maureen F. ZakowskiMZMaureen F. Zakowski
- Marc LadanyiMLMarc Ladanyi
- Mark G. KrisMKMark G. Kris
- 13 July 2006
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 355 (2) , 213-215
Abstract
Mutations in the epidermal growth factor receptor gene (EGFR) occur in 10 to 20 percent of non–small-cell lung cancers, specifically adenocarcinomas, and are associated with the response to EGFR tyrosine kinase inhibitors (erlotinib and gefitinib).1 However, the results of screening of small-cell lung cancers for EGFR mutations have been negative.2 Thus, small-cell lung cancers are not routinely tested for EGFR mutations, nor have they been systematically evaluated for responsiveness to EGFR tyrosine kinase inhibitors.Keywords
This publication has 5 references indexed in Scilit:
- EGFR mutation in gefitinib-responsive small-cell lung cancerAnnals of Oncology, 2005
- Rapid Polymerase Chain Reaction-Based Detection of Epidermal Growth Factor Receptor Gene Mutations in Lung AdenocarcinomasThe Journal of Molecular Diagnostics, 2005
- Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future DirectionsJournal of Clinical Oncology, 2005
- Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancerLung Cancer, 2005
- Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung CancersJNCI: Journal of the National Cancer Institute, 2005